Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid Arthritis
Authors' conclusion
These findings indicate patients with overall lower disease activity are more likely to remain in SDAI remission/LDA after switching from combination therapy to monotherapy.
Study context
- Population
- Patients with rheumatoid arthritis (RA) on methotrexate (MTX) + etanercept (ETN) who sustained SDAI remission (≤ 3.3) through a 24-week run-in period253 entered double-blind period
- Participants
- 371 patients
- Comparison
- MTX monotherapy vs ETN monotherapy vs continued MTX + ETN combination therapy after sustained SDAI remission
- Primary endpoint
- Baseline factors associated with SDAI remission or LDA at the end of the run-in and double-blind periods
- Follow-up
- End of 24-week run-in and 48-week double-blind periods
Methodological detailsphase III, multicenter, randomized withdrawal, double-blind, controlled, multivariate logistic regression
- Phase III
- Multicenter
- Randomized withdrawal
- Double-blind
- Controlled
- Multivariate logistic regression
Primary result
As reported in the abstract
Baseline factors associated with remission/LDA (adjusted)
- SDAI remission at end of run-in associated with younger age, longer duration of MTX treatment and less severe clinical disease variables
- Maintaining remission/low disease activity (LDA) at end of 48-week double-blind period associated with lower PtGA, lower CRP, rheumatoid factor (RF) negativity, longer RA duration in the MTX arm, shorter duration of ETN treatment and lower magnesium
- After adjusting for other factors
Original publication
Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid Arthritis. J Rheumatol. Published 15 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →